Meta AnalysisID 2404
曲普坦类和麦角胺类药物治疗偏头痛急性发作相关的心血管不良事件：观察性研究的系统评价
CRD42014007528
Which evidence coming from clinical practice is available on the cardiovascular safety of triptans and ergotamines for the acute treatment of migraine? Can triptans or ergotamines increase the risk of serious cardiovasc
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 2404
- Evidence Id
- 10962
- Core Evidence Id
- 10962
- Source Meta Analysis Id
- 2355
- Herb2 Meta Analysis Id
- HBMA002355
- Crd Id
- CRD42014007528
- Title
- Adverse cardiovascular events associated to triptans and ergotamines for the acute treatment of migraine: a systematic review of observational studies
- Review Question
- Which evidence coming from clinical practice is available on the cardiovascular safety of triptans and ergotamines for the acute treatment of migraine? Can triptans or ergotamines increase the risk of serious cardiovascular adverse events in migraineurs?
- Study Type Included
- Observational cohort or case-control studies reporting data on cardiovascular outcomes in patients exposed to triptans or ergotamines for the acute treatment of migraine attacks. Accordingly to the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines, we will use broad inclusion criteria and subgroup and/or sensitivity analyses will be considered on the basis of differences in design features, outcomes or quality of the included studies.
- Condition Being Studied
- Migraine patients exposed to triptans or ergotamines.
- Participant
- Studies concerning population of migraneurs will be included. No restriction with respect to specific age categories or gender will be applied.
- Animal
- Human Disease Modelled
- Intervention
- The review will include studies concerning patients exposed to at least one of the following drugs: - Triptans (sumatriptan, rizatriptan, zolmitriptan, naratriptan, eletriptan, almotriptan, frovatriptan); - Ergotamines (ergotamine or dihydroergotamine).
- Comparator Control
- Individuals not exposed/exposed in the past to triptans and/or to ergotamines.
- Main Outcome
- Any cardiovascular outcome from the included studies will be included in the review.
- Outcome Measure
- Additional Outcome
- None.
- Study Method
- Keyword
- Drug-Related Side Effects and Adverse Reactions; Ergotamines; Humans; Migraine Disorders; Tryptamines
- Contact
- giuseppe roberto [email protected]
- Organisational Affiliation
- Department of Medical and Surgical Sciences, Pharmacology Unit, University of Bologna, Bologna, Italy http://www.dimec.unibo.it/it
- Funding Source
- No funding.
- Other Selection Criteria
- Final Publication
- Roberto G, Raschi E, Piccinni C, Conti V, Vignatelli L, D'Alessandro R, De Ponti F, Poluzzi E. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: Systematic review of observational studies. Cephalalgia. 2014 Sep 22. pii: 0333102414550416. [Epub ahead of print]
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Italy
- Review Stage
- Review Completed published
- First Submission Date
- Registration Date
- 2014-02-13
- Anticipated Start Date
- 2013-11-15
- Anticipated Completion Date
- 2014-03-20
- Title Cn
- 曲普坦类和麦角胺类药物治疗偏头痛急性发作相关的心血管不良事件：观察性研究的系统评价
- Title En
- Adverse cardiovascular events associated to triptans and ergotamines for the acute treatment of migraine: a systematic review of observational studies
- Bilingual Status
- complete